February 27, 2024 Regulatory Bulletin from the Extraordinary General Meeting in LIDDS AB (PUBL) on 27 February 2024
January 9, 2024 Regulatory Bulletin from the Extraordinary General Meeting in LIDDS AB (PUBL) on 9 January 2024
July 6, 2023 Regulatory LIDDS announces closure of R&D project with Johnson & Johnson Enterprise Innovation Inc.
June 27, 2023 Regulatory LIDDS announces Cost Containment Measures to maximise the runway to reach a License Agreement
February 20, 2023 Regulatory LIDDS’ rights issue is registered and trading in Paid Subscribed Shares ceases
February 7, 2023 Regulatory Correction of pressrelease: LIDDS announces preliminary outcome in the Rights Issue
January 9, 2023 Regulatory Bulletin from the Extraordinary General Meeting in LIDDS AB (publ) on the 9 January 2023
February 24, 2022 Regulatory Complement to press release: Notice of Extraordinary General Meeting of LIDDS AB (publ)
February 22, 2022 Regulatory LIDDS secures financing of up to 40.8 MSEK to create foundation for new partnerships based on the NanoZolid® technology
November 15, 2021 Regulatory LIDDS Announces Appointment of Johan Harmenberg as Chief Medical Officer
October 4, 2021 Regulatory NanoZolid®-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy
June 2, 2021 Regulatory LIDDS carry out a directed share issue of and is provided with approximately MSEK 45
June 1, 2021 Regulatory LIDDS Announces Appointment of Jenni Björnulfson as New Chief Financial Officer
March 2, 2021 Regulatory LIDDS enters R&D agreement with potential exclusive, global product license option
October 26, 2020 Regulatory LIDDS’ NanoZolid-TLR9 agonist demonstrates strong and durable preclinical anti-tumoral effect
August 20, 2020 Regulatory LIDDS licensee, Puheng Pharma, evaluates a novel expeditated regulatory path for Liproca Depot in China
June 11, 2020 Regulatory LIDDS announces a capital raise of a total of approximately SEK 59.3 million and accordingly secures long-term financing
May 19, 2020 Regulatory Correction of press release: Liproca Phase IIb study results indicate cancer control
May 18, 2020 Regulatory LIDDS announces positive meeting with the Swedish Medical Products Agency, confirming the Liproca® Depot Phase III study design
March 25, 2020 Regulatory LIDDS announces positive preclinical data for NanoZolid®-TLR9 agonist project
February 11, 2020 Regulatory LIDDS: Last patient treated in Liproca® Depot open label extension study
January 9, 2020 Regulatory LIDDS obtains novel US product patent that significantly broadens protection on NanoZolid® pharmaceuticals
November 16, 2019 Regulatory LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met
November 7, 2019 Regulatory LIDDS licensee Jiangxi Puheng Pharma prepares for phase III trial in China
October 23, 2019 Regulatory LIDDS: Liproca® Depot open label extension study indicates PSA reduction for up to one year
September 24, 2019 Regulatory Preliminary results from Phase IIb Liproca® Depot dose-finding study show a strong maximum PSA decrease and sustained PSA reduction effect
May 6, 2019 Regulatory LIDDS: Liproca® Depot open label extension study indicates longer treatment intervals
May 2, 2019 Regulatory LIDDS develops its own proprietary product for intratumoral immunotherapy – Freedom to operate analysis done for the TLR9-agonist project
April 2, 2019 Regulatory LIDDS announces a novel TLR9 agonist project and plan for Phase I clinical trial
March 18, 2019 Regulatory LIDDS to evaluate a possible listing of the company’s shares on Nasdaq Stockholm’s Main Market during 2020
November 21, 2018 Regulatory LIDDS adds two major university clinics in Lithuania to speed up enrollment in ongoing Phase IIb study
July 30, 2018 Regulatory New STING study opens up multi-billion dollar cancer immunotherapy market for LIDDS unique NanoZolid® technology
June 7, 2018 Regulatory LIDDS: Major European Investment Funds invest 21,7 MSEK in a direct share issue
May 16, 2018 Regulatory LIDDS signs license agreement for prostate cancer drug Liproca® Depot with major Chinese pharma company
May 15, 2018 Regulatory LIDDS broadens the scope of its technology platform by verifying NanoZolid® as subcutaneous depot for systemic delivery
March 15, 2018 Regulatory LIDDS: NanoZolid® with cutting edge STING agonist becomes a key project for LIDDS in immuno-oncology field
February 8, 2018 Regulatory LIDDS: Liproca® Depot effects on prostate cancer to be presented at the Paris Symposium for Magnetic Resonance in Medicine
January 10, 2018 Regulatory LIDDS: NanoZolid® with immune-stimulating agent confirms efficacy in an additional cancer model
December 27, 2017 Regulatory LIDDS: NanoZolid® with immune-stimulating agent demonstrates significant efficacy
July 20, 2017 Regulatory LIDDS: LIDDS and Recipharm establish industrial manufacturing capabilities for a novel prostate cancer product
March 28, 2017 Regulatory LIDDS patenting pharmaceutical products with large biomolecules in NanoZolid® for immunotherapy
January 23, 2017 Regulatory LIDDS: Clear effects for local tumour treatment of lung cancer – promising preclinical results with NanoZolid® and cytostatics are to be published